

Disclosures

Personal Commercial (11)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Alleviant Medical, Inc.	Other - <i>Clinical Events Committee Member</i>	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
American Regent	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
AstraZeneca	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Bristol Myers Squibb	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Bristol Myers Squibb	Research/Research Grants	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Cytokinetics	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Cytokinetics	Research/Research Grants	None (\$0)	<i>Heart Failure and Cardiomyopathies</i>
Idorsia	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Prevention</i>
Novo Nordisk Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Roche	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Zoll	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>

Additional Personal Commercial Disclosures for Education Activities (5)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Knowledge to Practice	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Med Learning Group	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Medscape	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Peer Direct	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
Physicians' Education Resource, LLC	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Heart Failure and Cardiomyopathies</i>

Personal Organizational or Other Non-Commercial (3)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
American College of Cardiology	Research/Research Grants	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
National Institutes of Health	Research/Research Grants <i>± K23 Mentored Career Development Award Number K23HL166961 - funding start date 9/1/2023</i>	Significant (>= \$5,000)	<i>Heart Failure and Cardiomyopathies</i>
National Institutes of Health	Research/Research Grants <i>± KL2 Mentored Career Development Award (end date 6/30/2022)</i>	Significant (>= \$5,000)	<i>Other</i>

Clinical Trial Enroller (11)

Trial Name	Trial Sponsor	Trial Funding Source
GENETIC-DCM	Bristol Myers Squibb	
A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy	Bristol Myers Squibb	
DISCOVER-HCM	Bristol Myers Squibb	
Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants	Bristol-Myers Squibb Company	

Trial Name	Trial Sponsor	Trial Funding Source
EMBARK-HFpEF	Bristol-Myers Squibb Company	
A Phase 3, Multi-Center, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy	Cytokinetics	
SEQUOIA-HCM	Cytokinetics, Inc.	
REDWOOD-OLE	Cytokinetics, Inc.	
FOREST-HCM	Cytokinetics, Inc.	
MAPLE-HCM	Cytokinetics, Inc.	
A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (BAG3 DCM)	Pfizer	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/1/2025
URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/1/2025
URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 10/1/2025
URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 10/1/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.